S-1: Inspire Veterinary Faces Nasdaq Delisting Amidst Dilutive Financing

Inspire Veterinary Partners, a U.S. veterinary hospital operator, is awaiting a Nasdaq delisting decision while pursuing highly dilutive convertible note financing and reporting continued net losses despite some operational improvements.

Summary

• Inspire Veterinary Partners operates 14 veterinary hospitals across nine U.S. states, specializing in small animal general practice with plans to expand into mixed animal, critical, and emergency care.
• The company received a Nasdaq delisting notice on November 13, 2025, for failing to meet the minimum bid price requirement and is ineligible for a compliance period due to multiple reverse stock splits. A hearing was held on January 13, 2026, with a decision pending.
• To address liquidity and capital needs, the company is undertaking a private placement of secured convertible promissory notes, allowing a selling stockholder to resell up to 200,000,000 Class A common shares.
• This financing includes a $975,000 secured convertible promissory note (First Note) issued on December 31, 2025, with a 30% original issue discount, and a future Second Note of up to $650,000.
• The conversion price for these notes is highly dilutive, set at the lesser of $0.06 per share or 80% of the lowest traded price over 15 days, with a floor of $0.01 per share.
• The company will not receive any proceeds from the resale of these 200,000,000 shares by the selling stockholder.
• For the nine months ended September 30, 2025, total revenue decreased by 8% to $12,238,875, compared to $13,270,973 in the prior year period.
• However, the net loss for the nine months ended September 30, 2025, improved by 23% to $(7,975,878) from $(10,297,539) in the same period of 2024, primarily due to reduced interest expense and the divestiture of Kauai Veterinary Clinic.
• The company reported an accumulated deficit of $44,326,159 and negative working capital of $5,894,301 as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• The company increased its authorized Class A Common Stock to 700,000,000 shares on January 9, 2026.
• Recent debt-to-equity conversions include canceling $150,000 of a promissory note for 3,000,000 shares ($0.05/share) on December 18, 2025, and $250,000 for 25,000,000 shares ($0.01/share) on January 13, 2026.
• A consulting agreement with 622 Capital LLC on December 12, 2025, involved issuing 9,450,000 shares for business development services.

Sentiment

Score: 2

Explanation: The company faces severe challenges, including an imminent Nasdaq delisting, a "going concern" warning from its auditors, and is relying on highly dilutive financing that does not provide direct cash proceeds from the current offering. While net losses decreased, overall revenue declined for the nine-month period, and the company's financial health remains precarious.

Positives

• Net loss decreased by 23% for the nine months ended September 30, 2025, to $(7,975,878) from $(10,297,539) in the prior year.
• Net loss per share improved to $(1.55) for the nine months ended September 30, 2025, from $(2.64) in the prior year.
• Cash used in operating activities significantly decreased to $(3,555,276) for the nine months ended September 30, 2025, from $(9,328,339) in the prior year.
• Interest expense decreased by 51% for the nine months ended September 30, 2025, to $(1,385,891) from $(2,801,491) in the prior year.
• Total revenue for the three months ended September 30, 2025, increased by 7% to $4,316,132 compared to $4,049,025 in the same period of 2024.
• Service revenue for the three months ended September 30, 2025, increased by 6% to $3,138,670, and product revenue increased by 9% to $1,177,462.
• The company successfully acquired DeBary Animal Clinic on June 4, 2025, for $1,942,500, expanding its network.
• Nasdaq notified the company on August 26, 2025, that it complies with the minimum stockholders' equity requirement after a private placement of Series B convertible preferred stock.

Negatives

• Received a Nasdaq delisting notice on November 13, 2025, for failing to meet the minimum bid price requirement.
• Ineligible for a compliance period for Nasdaq listing due to multiple reverse stock splits (cumulative ratio of 250:1 or more over two years).
• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative working capital.
• Accumulated deficit of $44,326,159 as of September 30, 2025.
• Negative working capital of $5,894,301 as of September 30, 2025.
• Total revenue decreased by 8% for the nine months ended September 30, 2025, to $12,238,875.
• The new secured convertible promissory notes have highly dilutive conversion features (floor price of $0.01 per share) and the company will not receive proceeds from the resale of these shares.
• The company has incurred significant losses on debt extinguishment and modification, totaling $689,411 for the nine months ended September 30, 2025, and $2,134,218 for the year ended December 31, 2024.
• High effective interest rates on merchant cash advance agreements (up to 52%).
• Significant control of voting power (approximately 32%) by non-independent directors, officers, and their affiliates.
• The company has not adopted a policy prohibiting directors, officers, and employees from hedging or pledging company stock.

Risks

• Limited operating history and not profitable; may never become profitable.
• Failure to attract and keep senior management could impact operations and financial results.
• May need to raise additional capital, which could result in dilution or restrictive debt covenants.
• Incurs significant increased expenses and administrative burdens as a public company.
• Failure to manage acquisitions or strategic alliances effectively could have a material adverse effect.
• Acquiring other businesses may be unsuccessful and could dilute ownership.
• Ability to use net operating loss carryforwards may be limited by inability to generate future taxable income or by ownership changes (Code Section 382).
• Management lacks extensive experience as senior management of a public company, potentially diverting attention from day-to-day operations.
• Failure to maintain effective internal controls over financial reporting could adversely affect business, operating results, and stock price.
• Purchasing real estate with hospital acquisitions adds complexity and cost.
• Estimate of addressable market size may be inaccurate.
• May be unable to execute growth strategies successfully or manage and sustain growth.
• Difficulties recruiting and retaining skilled veterinarians due to shortages.
• Negative publicity regarding animal care could harm reputation and reduce sales/profitability.
• Quarterly operating results may fluctuate due to timing of expenses, acquisitions, and closures.
• Reputation and business may be harmed if computer network security or databases containing personal information are compromised.
• The animal health industry is highly competitive.
• May be unable to adequately protect intellectual property rights.
• May be subject to litigation.
• Natural disasters and other events beyond control could harm business.
• Various government regulations could limit or delay ability to develop and commercialize services or negatively impact business.
• Failure to comply with governmental regulations or expansion of new laws could adversely affect business or lead to fines/litigation.
• May fail to comply with regulations covering dispensing prescription pet medications, including controlled substances.
• Subject to environmental, health, and safety laws and regulations that could result in costs.
• Received a delisting notice from Nasdaq regarding Class A common stock and awaiting a decision from Nasdaq's Hearings Panel.
• If delisted, could face limited market quotations, reduced liquidity, "penny stock" designation, decreased news/analyst coverage, and decreased ability to raise future financing.
• Investors who buy shares at different times will likely pay different prices due to selling stockholder discretion.
• If securities or industry analysts do not publish research or issue adverse opinions, stock price and trading volume could decline.
• Does not intend to pay cash dividends for the foreseeable future.
• Shares will be subordinate to all debts and liabilities, increasing risk of losing entire investment.
• Board of directors may designate and issue new classes of stock (e.g., Class B, preferred stock) that could be superior to or adversely affect Class A holders.
• Non-independent directors, officers, and their affiliates control approximately 32% of voting power, potentially influencing corporate actions against other investors' interests.
• Trading price of Common Stock is volatile, potentially resulting in substantial losses.
• Sale or availability for sale of substantial amounts of Common Stock could adversely affect market price.
• As an emerging growth company and smaller reporting company, reduced disclosure requirements may make Common Stock less attractive to investors.
• May be deemed a controlled company under Nasdaq rules, but does not intend to rely on exemptions.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future as it develops and acquires veterinary hospitals. It plans to expand through acquisitions of existing general practice, mixed animal facilities, and critical/emergency care hospitals, targeting five to ten units per year. The company also intends to build out its digital and data capabilities and introduce new offerings, including tele-veterinarian services. Its ability to continue as a going concern is contingent upon obtaining additional financing and generating sufficient cash flow.

Management Comments

• "Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern."
• "The Company and its medical leadership teach and enable its medical staff to provide comprehensive medical care which is appropriate for each animal patient."
• "The Company believes these analyses help the Company ensure that its caseload is revenue positive to avoid clinicians spending time on patient work which underutilizes their time and erodes labor profitability."

Industry Context

The animal health industry is highly competitive and fragmented, with over 28,000 veterinary hospitals in the U.S., less than 25% of which have been consolidated. Competitors range from large national consolidators like Mars and NVA to numerous regional groups. Inspire Veterinary aims to differentiate itself through a broad employee equity offering, a personalized approach to acquiring and integrating hospitals that preserves local practices, customized coaching for clinicians, and a valuation process focused on long-term Return On Investment.

Comparison to Industry Standards

• The company aims for 70% to 80% of gross revenue from services, aligning with industry targets to protect against disruption from non-veterinary channels.
• Uses Revenue Per Patient Per day (RPP) and Average Patient Charge (APC) as "quality medicine metrics" to analyze comprehensive diagnostics and services, which is a common practice in the veterinary service industry.
• The valuation process for intangible assets uses a "Veterinary Services industry rate of 74%" for customer retention, which is a standard benchmark.
• Competitors like Mars and NVA collectively own approximately 4,000 hospitals, while Inspire has 14, indicating a significant scale difference.
• Inspire's strategy of allowing acquired locations to sustain their own practices and identities is presented as a differentiator from the "more homogenized model used by competitors."

Management Changes

Corporate Governance

Legal Proceedings

• The company is addressing a lawsuit in Ohio State Court against a former animal clinic and hospital owner for violating a non-compete agreement. The company anticipates a favorable judgment for compensation below a certain threshold.
• No other pending legal proceedings or threats of proceedings are mentioned.

Related Party Transactions

• Blue Heron Consulting (COO Charles Stith Keiser, CVO Dr. Charles Chuck Keiser): Incurred $94,043 in expenses for consulting services during the nine months ended September 30, 2025.
• Star Circle Advisory Group, LLC (owned/controlled by CEO Kimball Carr, former CFO Peter Lau, Director James Coleman, Director Richard Marten): Incurred $284,900 in expenses for financial consulting services in 2023 (agreement terminated Q4 2023).
• CEO's Warrant: Kimball Carr received a warrant to purchase 20 Class A common shares at $6,000 per share (exercise price) on January 1, 2023, in consideration for his personal guaranty of company loans.
• Sale of Kauai Veterinary Clinic (KVC): Sold on September 20, 2024, to Kauai RE Holdings LLC, where Charles Keiser, DVM (father of board member Charles Stith Keiser) is a member.
• Loans guaranteed by CEO Kimball Carr and Director Charles Stith Keiser.

Stakeholder Impact

• Shareholders: Significant potential for dilution from convertible notes and future equity raises. Risk of delisting from Nasdaq could severely impact liquidity and stock value. Existing shareholders will not receive proceeds from the resale of shares by the selling stockholder.
• Employees: Potential impact from staffing shortages of veterinarians and technicians. Employee Stock Option Plan offers broad equity, which could be a positive for retention.
• Creditors: Secured convertible notes and other debt are guaranteed by the CEO and a director, providing some security, but the "going concern" warning indicates elevated risk.
• Customers (Pet Owners): Continued expansion through acquisitions aims to provide broader access to veterinary services, including specialized care. Negative publicity regarding animal care could harm customer perception.

Next Steps

• Await Nasdaq Hearings Panel decision regarding continued listing.
• Seek additional funding through debt or equity financing to address going concern issues.
• Continue to acquire additional veterinary hospitals, clinics, and practices.
• Expand service offerings to include emergency care and mixed animal facilities.
• Build out digital and data capabilities.
• Implement tele-veterinarian services (requires significant IT investment).
• Obtain stockholder approval for issuing shares in excess of Nasdaq's 19.99% ownership threshold for certain financing agreements.
• Complete the issuance of the Second Note (up to $650,000 principal) upon S-1 effectiveness.

Key Dates

Recommendation

The company faces severe challenges, including an imminent Nasdaq delisting, a "going concern" warning from its auditors, and a reliance on highly dilutive financing instruments that will not provide direct cash to the company from the current offering. While there was a reduction in net loss, overall revenue declined for the nine-month period, and the company's financial position remains precarious with a substantial accumulated deficit and negative working capital. The significant potential for further dilution from the convertible notes, coupled with the uncertainty of Nasdaq listing, makes this a high-risk investment with substantial downside.

Keywords

veterinary hospitals, pet care, animal health, Nasdaq delisting, convertible notes, dilution, SEC filing, S-1, financial performance, acquisitions, going concern, risk factors, corporate governance, capital raise, IVP, small animal practice, equine care, emergency care